- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Marker Therapeutics Inc (MRKR)
The Marker Therapeutics share price today is 1.390, view NASDAQ MRKR stock exchange data. Track the latest Marker Therapeutics share price with real-time updates on MRKR stock performance including market cap, day range, 52-week range and dividend yield. Access MRKR charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.390
1.440
52 wk Range
0.810
4.070
MRKR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3901.440
52 wk Range
0.8104.070
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRKR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.867
Upside
+465.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form PRE 14A Marker Therapeutics For: 10 March
- Investing.com
- Form PRE 14A Marker Therapeutics For: 10 March
- Investing.com
- Form 8K Marker Therapeutics Inc For: 9 February
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.867
(+465.95% Upside)
Earnings
Latest Release
18-03-2026
EPS / Forecast
-0.09 / -0.77
Revenue / Forecast
1.1M / --
Compare MRKR to Peers and Sector
Metrics to compare | MRKR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −5.6x | −0.5x | |
PEG Ratio | −0.04 | −0.10 | 0.00 | |
Price/Book | 1.7x | 3.0x | 2.6x | |
Price / LTM Sales | 6.5x | 32.8x | 3.2x | |
Upside (Analyst Target) | - | 90.6% | 55.3% | |
Fair Value Upside | Unlock | −6.0% | 9.7% | Unlock |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Marker Therapeutics (MRKR) Share Price Today?
The Marker Therapeutics share price today is 1.390.
What is the current Marker Therapeutics (MRKR) share price and day range?
As of 19-05-2026, the Marker Therapeutics share price is 1.390, with a previous close of 1.390. The share price has ranged from 1.390 to 1.440 today, while the 52-week range spans from 0.810 to 4.070.
What Is the Marker Therapeutics Market Cap?
As of today, Marker Therapeutics market cap is 23.180M.
What Is the Marker Therapeutics (MRKR) Share Price Target?
The average 12-month share price target for Marker Therapeutics is 7.867, with a high estimate of 10 and a low estimate of 5.6. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +465.95% Upside potential.
What Is Marker Therapeutics's Earnings Per Share (TTM)?
The Marker Therapeutics EPS (TTM) is -0.628.
From a Technical Analysis Perspective, Is MRKR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Marker Therapeutics Trade On?
Marker Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Marker Therapeutics?
The stock symbol for Marker Therapeutics is "MRKR."
How Many Times Has Marker Therapeutics Stock Split?
Marker Therapeutics has split 5 times.
How Many Employees Does Marker Therapeutics Have?
Marker Therapeutics has 5 employees.
What Is the MRKR After Hours Price?
MRKR's last after hours stock price is 1.440, the stock has changed by 0.050, or 3.600%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.